Statement of Organization, Functions, and Delegations of Authority, 65901-65902 [05-21672]

Download as PDF Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices PACHA was established by Executive Order 12963, dated June 14, 1995, as amended by Executive Order 13009, dated June 14, 1996. PACHA was established to provide advice, information, and recommendations to the President regarding programs and policies intended to (a) promote effective prevention of HIV disease, (b) advance research on HIV and AIDS, and (c) promote quality services to persons living with HIV disease and AIDS. PACHA was established to serve solely as an advisory body to the President and the Secretary of Health and Human Services. PACHA is composed of not more than 21 members. PACHA membership is determined by the Secretary from individuals who are considered authorities with particular expertise in, or knowledge of, matters concerning HIV/AIDS. The agenda for this meeting includes the following topics: HIV/AIDS prevention, care and treatment, and global HIV/AIDS issues. Time will be allotted during the meeting for public comment. Public attendance is limited to space available and pre-registration is required for both attendance and public comment. Any individual who wishes to attend and/or comment must register on-line at https://www.pacha.gov. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should indicate when registering on-line. Members of the public will have the opportunity to provide comments at the meeting. Public comment will be limited to three (3) minutes per speaker and to time available. Written testimony, not exceed five (5) pages, will be accepted by mail or facsimile at 202/205–4986. Written testimony will not be accepted after 5 p.m., Wednesday, November 9, 2005. SUPPLEMENTARY INFORMATION: Dated: October 26, 2005. Joseph Grogan, Executive Director, Presidential Advisory Council on HIV/AIDS. [FR Doc. 05–21714 Filed 10–31–05; 8:45 am] BILLING CODE 4150–43–P VerDate Aug<31>2005 15:39 Oct 31, 2005 Jkt 208001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Statement of Organization, Functions, and Delegations of Authority Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 30, 1980, as amended most recently at 69 FR 77756, dated December 28, 2004) is amended to reorganize the National Center for HIV, STD, & TB Prevention. Section C–B, Organization and Functions, is hereby amended as follows: Delete in its entirety the following titles and functional statements: Division of AIDS, STD & TB Laboratory Research (CK7), Office of the Director (CK71), HIV, Immunology and Diagnostics Branch (CK72), HIV Immunology and Diagnostics Branch (CK73), Sexually Transmitted Infectious Diseases Branch (CK74), Tuberculosis/ Mycobacteriology Branch (CK75). Following the Training and Health Communication Branch (CK37), Division of STD Prevention (CK3), insert the following: Laboratory Reference and Research Branch, (CK38). (1) Performs research on the pathogenesis, genetics, and immunology of syphilis and other treponematoses, gonococcal and chlamydial infections, chancroid, genital herpes, donovanosis, bacterial vaginosis and trichomoniasis; (2) conducts and participates in clinical, field, and laboratory research to develop, evaluate, and improve laboratory methods used in the diagnosis and epidemiology of these sexually transmitted infections (STIs); (3) provides consultation and reference/ diagnostic services for these STIs; (4) conducts laboratory-based surveillance for and research on the genetics of antimicrobial resistance in Neisseria gonorrhoeae; (5) serves as the WHO International Collaborating Center for Reference and Research in Syphilis Serology; and (6) provides consultation and laboratory support for international activities. Following the International Research and Programs Branch (CK47), Division of Tuberculosis Elimination (CK4), insert the following: Mycobacteriology Branch (HCK48). (1) Provides laboratory support for PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 65901 epidemic investigations, surveillance activities, and special studies of tuberculosis and other mycobacteriacaused diseases; (2) administers contracts to provide Mycobacterium tuberculosis genotyping, maintains a national database of genotypes, and conducts operational research to implement genotyping; (3) develops and evaluates new methods to subtype mycobacteria for epidemiologic studies; (4) serves as primary CDC focus for diagnostic mycobacteriology laboratory services and for laboratory aspects of nontuberculosis Mycobacterium species and of Hansen disease (leprosy); (5) administers grants and cooperative agreements with states and others to upgrade laboratory activities and provide special services; (6) provides reference diagnostic services, consultation, technical assistance, and training to State, Federal, and municipal public health laboratories; (7) provides laboratory support, reference services, assessment, consultation, and training for CDC’s international tuberculosis activities; (8) develops, evaluates, or improves conventional and molecular methods for the detection, classification, identification, characterization, and susceptibility testing of mycobacteria and mycobacteria-caused diseases; (9) conducts studies to define the role of bacterial virulence factors, host factors, and pathogenic and immunologic mechanisms in disease processes and protective immunity and develops, evaluates, and improves immunologic methods for the diagnosis and prevention of mycobacteria-caused diseases; (10) develops tissue culture and animal models of mycobacteriacaused diseases and conducts studies on chemotherapy, immunotherapy, pathogenesis, pathology, and vaccines for mycobacteria-caused diseases; (11) conducts studies on the isolation, taxonomy, and ecology of mycobacteria and develops tests to identify new species; (12) conducts and supports studies to characterize newly emerging pathogenic species of Mycobacterium and associated diseases. Following the HIV Incidence and Case Surveillance Branch (CK56), Division of HIV, AIDS Prevention— Surveillance and Epidemiology (CK5), insert the following: HIV and Retrovirology Laboratory Branch (HCK57). (1) Conducts studies of human immunodeficiency viruses (HIVs) and other human and zoonotic retroviruses, including the diseases they cause, their modes of transmission, and the means for their control through virus detection, isolation, and characterization by virologic, molecular, and cellular biologic methods; (2) E:\FR\FM\01NON1.SGM 01NON1 65902 Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices collaborates with NCHSTP investigators to conduct HIV epidemiologic and surveillance studies worldwide particularly as they pertain to prevention and intervention strategies; (3) identifies and characterizes new HIV isolates and develops new screening tests for these isolates to determine their prevalence in various populations; (4) determines geotypic and phenotypic variations of HIVs that may affect pathogenesis, drug resistance, persistence, virulence, and transmissibility; (5) conducts and supports field epidemiologic investigations of the prevalence, distribution, trends, and risk factors associated with non-AIDS retroviral infections and associated diseases; (6) serves as a World Health Organization (WHO) Reference Center and as a member of the UNAIDS Virus Network to provide international consultation and technical assistance on laboratory procedures for HIV isolation, detection, and characterization; (7) develops and evaluates procedures for the isolation and characterization of HIV and for the detection of retroviral DNA or RNA from clinical samples; (8) provides training, reference testing, and reference reagents for virologic and molecular characterization of divergent HIVs for public health laboratories in the United States and WHO; (9) serves as a reference laboratory for the isolation of zoonotic retroviruses from clinical samples; (10) develops collaborations with other CDC and non-CDC scientists to promote scientific progress and accomplishments; and (11) collaborates with industry to promote commercialization of useful technology, methodologies, and reagents of public health importance. HIV Immunology and Diagnostic Laboratory Branch (HCK58). (1) Conducts basic and applied studies of microbial-host interactions that occur in infections, particularly infection with human immunodeficiency virus (HIV); (2) conducts basic and applied investigations of the immune cell interactions that occur in HIV infection as well as in related immunologic/ infectious diseases; conducts investigations of genetic traits of the host that influence the susceptibility, disease course, and immune response to infectious disease, particularly HIV diseases; (3) conducts studies related to the development, evaluation, improvement, and standardization of laboratory technologies uses for the diagnosis, surveillance, and monitoring of HIV infection both independently and in collaboration with the biotechnology industry; (4) performs VerDate Aug<31>2005 15:39 Oct 31, 2005 Jkt 208001 HIV antigen and antibody testing plus related standardized assays in support of the diagnostic/surveillance/ epidemiologic requirements of CDCbased and CDC-affiliated studies of the HIV epidemic; (5) serves as a reference laboratory for State and local health departments; and (6) provides diagnostic services to other Federal agencies, the World Health Organization, CDC-affiliated academic centers, CDC-affiliated studies with other countries, and community organizations, as appropriate. Dated: April 1, 2005. William H. Gimson, Chief Operating Officer, Centers for Disease Control and Prevention (CDC). [FR Doc. 05–21672 Filed 10–31–05; 8:45 am] BILLING CODE 4160–18–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare and Medicaid Services Notice of Grant Award to MedCO Health Solutions, Inc., To Evaluate an Open-Source Project Entitled, ‘‘A Comparison of Multiple Methods to Incent Physicians To Adopt Electronic Prescribing Devices’’ Centers for Medicare and Medicaid Services (CMS), HHS. ACTION: Notice of Grant Award. AGENCY: SUMMARY: The Centers for Medicare and Medicaid Services has awarded a grant entitled, ‘‘A Comparison of Multiple Methods To Incent Physicians To Adopt Electronic Prescribing Devices’’ to Medco Health Solutions, Inc., 100 Parsons Pond Drive, Franklin Lakes, NJ 07417 in response to an unsolicited proposal. The period of performance is August 1, 2005 through July 31, 2006. The purpose of this grant is to fund an initial evaluation of the Southeastern Michigan e-Prescribing Initiative (SEMI) project. Through the use of eprescribing, this program is intended to reduce the costs associated with the use of prescription drugs, and improve safety for patients, including Medicare beneficiaries, associated with an estimated 6,000 targeted physicians/ prescribers in Southeastern Michigan. The project involves the active collaboration of multiple employers, insurance entities and care providers in eight counties in Southeastern Michigan. Partners include the Big Three automakers, Ford, General Motors and Daimler Chrysler; Blue Cross/Blue Shield of Michigan; Henry Ford Health System/Health Alliance Plan; Health PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 Plus of Michigan; SureScripts, RxHub and MedCo. This is a unique project in terms of size, sponsoring organizations, patient base, geographic area, and approach. This project is consistent with CMS’ goals to improve health care quality, patient safety, and the use of electronic prescribing. Funding of this unsolicited proposal will result in a desirable public benefit in that its aim is to provide needed information on the costs and critical success factors associated with the adoption of electronic prescribing, as well as to provide improvements in quality and safety of care delivery. FOR FURTHER INFORMATION CONTACT: Maria Friedman, Project Officer, Office of e-health Standards and Services, Centers for Medicare and Medicaid Services, 7500 Security Blvd., Stop S2– 27–17, Baltimore, MD 21244, (410) 786– 6333 or Judy Norris, Grants Officer, Department of Health and Human Services, OOM/AGG/CMS, 7500 Security Blvd., Stop S2–21–15, Baltimore, MD 21244, (410) 786–5130. Authority: Catalog of Federal Domestic Assistance Program No. 93–779, Center for Medicare and Medicaid Services, Research, Demonstrations and Evaluations; Section 1110 of the Social Security Act. Dated: August 9, 2005. Mark B. McClellan, Administrator, Centers for Medicare and Medicaid Services. [FR Doc. 05–21731 Filed 10–31–05; 8:45 am] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Submission for OMB Review; Comment Request Title: The National Evaluation of the Court Improvement Program. OMB No.: New Collection. Description: The National Evaluation of the Court Improvement Program will describe the many paths followed by state courts to improve their oversight of child welfare cases, and will provide the field with information on effective models for juvenile and family court reform. Funded by the Children’s Bureau, U.S. Department of Health and Human Services (HHS) in 2004, the fiveyear study is being carried out by a partnership of three organizations consisting of Planning and Learning Technologies (Pal-Tech, Inc.), the Urban Institute and the Center for Policy Research. E:\FR\FM\01NON1.SGM 01NON1

Agencies

[Federal Register Volume 70, Number 210 (Tuesday, November 1, 2005)]
[Notices]
[Pages 65901-65902]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-21672]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Statement of Organization, Functions, and Delegations of 
Authority

    Part C (Centers for Disease Control and Prevention) of the 
Statement of Organization, Functions, and Delegations of Authority of 
the Department of Health and Human Services (45 FR 67772-76, dated 
October 14, 1980, and corrected at 45 FR 69296, October 30, 1980, as 
amended most recently at 69 FR 77756, dated December 28, 2004) is 
amended to reorganize the National Center for HIV, STD, & TB 
Prevention.
    Section C-B, Organization and Functions, is hereby amended as 
follows:
    Delete in its entirety the following titles and functional 
statements: Division of AIDS, STD & TB Laboratory Research (CK7), 
Office of the Director (CK71), HIV, Immunology and Diagnostics Branch 
(CK72), HIV Immunology and Diagnostics Branch (CK73), Sexually 
Transmitted Infectious Diseases Branch (CK74), Tuberculosis/
Mycobacteriology Branch (CK75).
    Following the Training and Health Communication Branch (CK37), 
Division of STD Prevention (CK3), insert the following:
    Laboratory Reference and Research Branch, (CK38). (1) Performs 
research on the pathogenesis, genetics, and immunology of syphilis and 
other treponematoses, gonococcal and chlamydial infections, chancroid, 
genital herpes, donovanosis, bacterial vaginosis and trichomoniasis; 
(2) conducts and participates in clinical, field, and laboratory 
research to develop, evaluate, and improve laboratory methods used in 
the diagnosis and epidemiology of these sexually transmitted infections 
(STIs); (3) provides consultation and reference/diagnostic services for 
these STIs; (4) conducts laboratory-based surveillance for and research 
on the genetics of antimicrobial resistance in Neisseria gonorrhoeae; 
(5) serves as the WHO International Collaborating Center for Reference 
and Research in Syphilis Serology; and (6) provides consultation and 
laboratory support for international activities.
    Following the International Research and Programs Branch (CK47), 
Division of Tuberculosis Elimination (CK4), insert the following:
    Mycobacteriology Branch (HCK48). (1) Provides laboratory support 
for epidemic investigations, surveillance activities, and special 
studies of tuberculosis and other mycobacteria-caused diseases; (2) 
administers contracts to provide Mycobacterium tuberculosis genotyping, 
maintains a national database of genotypes, and conducts operational 
research to implement genotyping; (3) develops and evaluates new 
methods to subtype mycobacteria for epidemiologic studies; (4) serves 
as primary CDC focus for diagnostic mycobacteriology laboratory 
services and for laboratory aspects of nontuberculosis Mycobacterium 
species and of Hansen disease (leprosy); (5) administers grants and 
cooperative agreements with states and others to upgrade laboratory 
activities and provide special services; (6) provides reference 
diagnostic services, consultation, technical assistance, and training 
to State, Federal, and municipal public health laboratories; (7) 
provides laboratory support, reference services, assessment, 
consultation, and training for CDC's international tuberculosis 
activities; (8) develops, evaluates, or improves conventional and 
molecular methods for the detection, classification, identification, 
characterization, and susceptibility testing of mycobacteria and 
mycobacteria-caused diseases; (9) conducts studies to define the role 
of bacterial virulence factors, host factors, and pathogenic and 
immunologic mechanisms in disease processes and protective immunity and 
develops, evaluates, and improves immunologic methods for the diagnosis 
and prevention of mycobacteria-caused diseases; (10) develops tissue 
culture and animal models of mycobacteria-caused diseases and conducts 
studies on chemotherapy, immunotherapy, pathogenesis, pathology, and 
vaccines for mycobacteria-caused diseases; (11) conducts studies on the 
isolation, taxonomy, and ecology of mycobacteria and develops tests to 
identify new species; (12) conducts and supports studies to 
characterize newly emerging pathogenic species of Mycobacterium and 
associated diseases.
    Following the HIV Incidence and Case Surveillance Branch (CK56), 
Division of HIV, AIDS Prevention--Surveillance and Epidemiology (CK5), 
insert the following:
    HIV and Retrovirology Laboratory Branch (HCK57). (1) Conducts 
studies of human immunodeficiency viruses (HIVs) and other human and 
zoonotic retroviruses, including the diseases they cause, their modes 
of transmission, and the means for their control through virus 
detection, isolation, and characterization by virologic, molecular, and 
cellular biologic methods; (2)

[[Page 65902]]

collaborates with NCHSTP investigators to conduct HIV epidemiologic and 
surveillance studies worldwide particularly as they pertain to 
prevention and intervention strategies; (3) identifies and 
characterizes new HIV isolates and develops new screening tests for 
these isolates to determine their prevalence in various populations; 
(4) determines geotypic and phenotypic variations of HIVs that may 
affect pathogenesis, drug resistance, persistence, virulence, and 
transmissibility; (5) conducts and supports field epidemiologic 
investigations of the prevalence, distribution, trends, and risk 
factors associated with non-AIDS retroviral infections and associated 
diseases; (6) serves as a World Health Organization (WHO) Reference 
Center and as a member of the UNAIDS Virus Network to provide 
international consultation and technical assistance on laboratory 
procedures for HIV isolation, detection, and characterization; (7) 
develops and evaluates procedures for the isolation and 
characterization of HIV and for the detection of retroviral DNA or RNA 
from clinical samples; (8) provides training, reference testing, and 
reference reagents for virologic and molecular characterization of 
divergent HIVs for public health laboratories in the United States and 
WHO; (9) serves as a reference laboratory for the isolation of zoonotic 
retroviruses from clinical samples; (10) develops collaborations with 
other CDC and non-CDC scientists to promote scientific progress and 
accomplishments; and (11) collaborates with industry to promote 
commercialization of useful technology, methodologies, and reagents of 
public health importance.
    HIV Immunology and Diagnostic Laboratory Branch (HCK58). (1) 
Conducts basic and applied studies of microbial-host interactions that 
occur in infections, particularly infection with human immunodeficiency 
virus (HIV); (2) conducts basic and applied investigations of the 
immune cell interactions that occur in HIV infection as well as in 
related immunologic/infectious diseases; conducts investigations of 
genetic traits of the host that influence the susceptibility, disease 
course, and immune response to infectious disease, particularly HIV 
diseases; (3) conducts studies related to the development, evaluation, 
improvement, and standardization of laboratory technologies uses for 
the diagnosis, surveillance, and monitoring of HIV infection both 
independently and in collaboration with the biotechnology industry; (4) 
performs HIV antigen and antibody testing plus related standardized 
assays in support of the diagnostic/surveillance/epidemiologic 
requirements of CDC-based and CDC-affiliated studies of the HIV 
epidemic; (5) serves as a reference laboratory for State and local 
health departments; and (6) provides diagnostic services to other 
Federal agencies, the World Health Organization, CDC-affiliated 
academic centers, CDC-affiliated studies with other countries, and 
community organizations, as appropriate.

    Dated: April 1, 2005.
William H. Gimson,
Chief Operating Officer, Centers for Disease Control and Prevention 
(CDC).
[FR Doc. 05-21672 Filed 10-31-05; 8:45 am]
BILLING CODE 4160-18-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.